Physician profile
Thomas N Hoffman
NPI 1912997628
$17,466.53
in general payments reported to CMS, 2019-2025
27 companies · $3,752 in 2025
The $3,752 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $472 · 2021: $2,554 · 2022: $3,130 · 2023: $4,028 · 2024: $3,304 · 2025: $3,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,084.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,079.45 | 2020-2025 | Tavneos, Otezla, Enbrel |
| Abbvie INC. | $2,732.41 | 2019-2025 | |
| Ucb, INC. | $2,296.41 | 2020-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,770.55 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,351.30 | 2020-2025 | |
| Horizon Therapeutics Plc | $973.39 | 2019-2023 | Krystexxa |
| Pfizer INC. | $945.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $755.93 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $655.52 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $653.42 | 2020-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $533.35 | 2020-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $323.10 | 2024-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $251.74 | 2021-2025 | Actemra, Rituxan |
| Organon LLC | $211.66 | 2022-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $172.80 | 2023-2025 | Idacio, Tyenne |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $152.55 | 2021-2025 | Strensiq |
| Radius Health, INC. | $139.77 | 2020 | |
| Pacira Therapeutics, INC. | $107.16 | 2021 | |
| Aurinia Pharma U.S., INC. | $101.90 | 2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.77 | 2023-2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $42.43 | 2021-2023 | Euflexxa |
| Grt US Holding, INC. | $30.66 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $28.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.73 | 2022 | |
| Neurometrix INC | $19.75 | 2023 | |
| Sandoz INC. | $17.44 | 2025 | Jubbonti |
| Fidia Pharma USA INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.